Literature DB >> 18684712

Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva.

Toru Fukuda1, Masakazu Kohda, Kazuhiro Kanomata, Junya Nojima, Atsushi Nakamura, Jyunji Kamizono, Yasuo Noguchi, Kiyofumi Iwakiri, Takeo Kondo, Junichi Kurose, Ken-ichi Endo, Takeshi Awakura, Junichi Fukushi, Yasuharu Nakashima, Tomohiro Chiyonobu, Akira Kawara, Yoshihiro Nishida, Ikuo Wada, Masumi Akita, Tetsuo Komori, Konosuke Nakayama, Akira Nanba, Yuichi Maruki, Tetsuya Yoda, Hiroshi Tomoda, Paul B Yu, Eileen M Shore, Frederick S Kaplan, Kohei Miyazono, Masaru Matsuoka, Kenji Ikebuchi, Akira Ohtake, Hiromi Oda, Eijiro Jimi, Ichiro Owan, Yasushi Okazaki, Takenobu Katagiri.   

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder characterized by congenital malformation of the great toes and by progressive heterotopic bone formation in muscle tissue. Recently, a mutation involving a single amino acid substitution in a bone morphogenetic protein (BMP) type I receptor, ALK2, was identified in patients with FOP. We report here that the identical mutation, R206H, was observed in 19 Japanese patients with sporadic FOP. This mutant receptor, ALK2(R206H), activates BMP signaling without ligand binding. Moreover, expression of Smad1 and Smad5 was up-regulated in response to muscular injury. ALK2(R206H) with Smad1 or Smad5 induced osteoblastic differentiation that could be inhibited by Smad7 or dorsomorphin. Taken together, these findings suggest that the heterotopic bone formation in FOP may be induced by a constitutively activated BMP receptor signaling through Smad1 or Smad5. Gene transfer of Smad7 or inhibition of type I receptors with dorsomorphin may represent strategies for blocking the activity induced by ALK2(R206H) in FOP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18684712      PMCID: PMC2652274          DOI: 10.1074/jbc.M801681200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  In vivo somatic cell gene transfer of an engineered Noggin mutein prevents BMP4-induced heterotopic ossification.

Authors:  David L Glaser; Aris N Economides; Lili Wang; Xia Liu; Robert D Kimble; James P Fandl; James M Wilson; Neil Stahl; Frederick S Kaplan; Eileen M Shore
Journal:  J Bone Joint Surg Am       Date:  2003-12       Impact factor: 5.284

Review 2.  Fibrodysplasia ossificans progressiva: a clue from the fly?

Authors:  F S Kaplan; J A Tabas; M A Zasloff
Journal:  Calcif Tissue Int       Date:  1990-08       Impact factor: 4.333

3.  Bone: formation by autoinduction.

Authors:  M R Urist
Journal:  Science       Date:  1965-11-12       Impact factor: 47.728

4.  The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients.

Authors:  R B Cohen; G V Hahn; J A Tabas; J Peeper; C L Levitz; A Sando; N Sando; M Zasloff; F S Kaplan
Journal:  J Bone Joint Surg Am       Date:  1993-02       Impact factor: 5.284

5.  Identification of a BMP-responsive element in Id1, the gene for inhibition of myogenesis.

Authors:  Takenobu Katagiri; Mana Imada; Takeshi Yanai; Tatsuo Suda; Naoyuki Takahashi; Ryutaro Kamijo
Journal:  Genes Cells       Date:  2002-09       Impact factor: 1.891

6.  Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients.

Authors:  J M Connor; D A Evans
Journal:  J Bone Joint Surg Br       Date:  1982

Review 7.  Skeletal metamorphosis in fibrodysplasia ossificans progressiva (FOP).

Authors:  Frederick S Kaplan; Qi Shen; Vitali Lounev; Petra Seemann; Jay Groppe; Takenobu Katagiri; Robert J Pignolo; Eileen M Shore
Journal:  J Bone Miner Metab       Date:  2008-11-01       Impact factor: 2.626

8.  The histopathology of fibrodysplasia ossificans progressiva. An endochondral process.

Authors:  F S Kaplan; J A Tabas; F H Gannon; G Finkel; G V Hahn; M A Zasloff
Journal:  J Bone Joint Surg Am       Date:  1993-02       Impact factor: 5.284

9.  Novel regulators of bone formation: molecular clones and activities.

Authors:  J M Wozney; V Rosen; A J Celeste; L M Mitsock; M J Whitters; R W Kriz; R M Hewick; E A Wang
Journal:  Science       Date:  1988-12-16       Impact factor: 47.728

10.  Synergistic effects of different bone morphogenetic protein type I receptors on alkaline phosphatase induction.

Authors:  H Aoki; M Fujii; T Imamura; K Yagi; K Takehara; M Kato; K Miyazono
Journal:  J Cell Sci       Date:  2001-04       Impact factor: 5.285

View more
  89 in total

1.  BMP3 suppresses osteoblast differentiation of bone marrow stromal cells via interaction with Acvr2b.

Authors:  Shoichiro Kokabu; Laura Gamer; Karen Cox; Jonathan Lowery; Kunikazu Tsuji; Regina Raz; Aris Economides; Takenobu Katagiri; Vicki Rosen
Journal:  Mol Endocrinol       Date:  2011-11-10

2.  Fibrodysplasia ossificans progressiva: a human genetic disorder of extraskeletal bone formation, or--how does one tissue become another?

Authors:  Eileen M Shore
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2012 Jan-Feb       Impact factor: 5.814

3.  Multipotent progenitors resident in the skeletal muscle interstitium exhibit robust BMP-dependent osteogenic activity and mediate heterotopic ossification.

Authors:  Michael N Wosczyna; Arpita A Biswas; Catherine A Cogswell; David J Goldhamer
Journal:  J Bone Miner Res       Date:  2012-05       Impact factor: 6.741

4.  Accumulation of p100, a precursor of NF-κB2, enhances osteoblastic differentiation in vitro and bone formation in vivo in aly/aly mice.

Authors:  Yoshinori Seo; Hidefumi Fukushima; Toshimasa Maruyama; Kayoko Nakao Kuroishi; Kenji Osawa; Kenichi Nagano; Kazuhiro Aoki; Falk Weih; Takahiro Doi; Min Zhang; Keiichi Ohya; Takenobu Katagiri; Ryuji Hosokawa; Eijiro Jimi
Journal:  Mol Endocrinol       Date:  2012-01-26

5.  Investigations of activated ACVR1/ALK2, a bone morphogenetic protein type I receptor, that causes fibrodysplasia ossificans progressiva.

Authors:  Frederick S Kaplan; Petra Seemann; Julia Haupt; Meiqi Xu; Vitali Y Lounev; Mary Mullins; Eileen M Shore
Journal:  Methods Enzymol       Date:  2010       Impact factor: 1.600

Review 6.  Application of human induced pluripotent stem cells to model fibrodysplasia ossificans progressiva.

Authors:  Emilie Barruet; Edward C Hsiao
Journal:  Bone       Date:  2017-07-14       Impact factor: 4.398

7.  Strategic Targeting of Multiple BMP Receptors Prevents Trauma-Induced Heterotopic Ossification.

Authors:  Shailesh Agarwal; Shawn J Loder; Christopher Breuler; John Li; David Cholok; Cameron Brownley; Jonathan Peterson; Hsiao H Hsieh; James Drake; Kavitha Ranganathan; Yashar S Niknafs; Wenzhong Xiao; Shuli Li; Ravindra Kumar; Ronald Tompkins; Michael T Longaker; Thomas A Davis; Paul B Yu; Yuji Mishina; Benjamin Levi
Journal:  Mol Ther       Date:  2017-07-15       Impact factor: 11.454

8.  A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date.

Authors:  Celia L Gregson; Peter Hollingworth; Martin Williams; Kirsten A Petrie; Alex N Bullock; Matthew A Brown; Jon H Tobias; James T Triffitt
Journal:  Bone       Date:  2010-10-29       Impact factor: 4.398

Review 9.  Fibrodysplasia ossificans progressiva (FOP): A disorder of osteochondrogenesis.

Authors:  Frederick S Kaplan; Mona Al Mukaddam; Alexandra Stanley; O Will Towler; Eileen M Shore
Journal:  Bone       Date:  2020-07-27       Impact factor: 4.398

10.  mTOR inhibition and BMP signaling act synergistically to reduce muscle fibrosis and improve myofiber regeneration.

Authors:  Shailesh Agarwal; David Cholok; Shawn Loder; John Li; Christopher Breuler; Michael T Chung; Hsiao Hsin Sung; Kavitha Ranganathan; Joe Habbouche; James Drake; Joshua Peterson; Caitlin Priest; Shuli Li; Yuji Mishina; Benjamin Levi
Journal:  JCI Insight       Date:  2016-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.